A Pilot Trial of 13-cis Retinoic Acid (Isotretinoin) for the Treatment of Men With Oligoasthenoteratozoospermia
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Millions of Sperm Per Ejaculate
研究概览
简要总结
Men with infertility and normal hormone levels have few options for fertility treatment. Previous research work has suggested that men with infertility may have low levels of the active form of Vitamin A, called retinoic acid, in their testes. We think that giving men with low sperm counts retinoic acid may increase their sperm counts and improve their chances of fathering a pregnancy. We want to see if retinoic acid administration over twenty weeks can increase sperm production and help infertile men become fathers without the need for In vitro fertilization (IVF) and/or intracytoplasmic sperm injection (ICSI). We also want to see if adding calcitriol with retinoic acid will improve sperm motility in a sub-set of subjects.
详细描述
This is a 20 week, unblinded, two-arm pilot study to determine the impact of therapy with 13-cis retinoic acid and calcitriol on sperm indices in infertile men. Twenty infertile men, ages 21-60 with abnormal sperm analyses will be enrolled for 20-week and given 20 mg 13-cis retinoic acid, twice daily. Subjects#11-#20 will also be administered calcitriol to see if adding calcitriol with Accutane will improve sperm motility. All subjects will be closely followed for side effects related to treatment. The impact of treatment on indices of spermatogenesis will be determined by monthly seminal fluid analyses.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 60 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Subjects will be infertile men (no pregnancy with partner with normal cycles and normal hysterosalpingogram despite >1 year of unprotected intercourse).
- •Abnormal sperm analyses with a total, motile sperm count of less than 10 million sperm as assessed by semen analysis on two occasions separated by one week.
- •In the opinion of the investigator, is able to comply with the protocol, understand and sign an informed consent and HIPAA (Health Insurance Portability and Accountability Act ) form.
排除标准
- •Men participating in another clinical trial
- •Men not living in the catchment area of the clinic
- •Clinically significant abnormal findings at screening
- •Known genetic infertility (e.g. Klinefelter syndrome or Y-chromosome microdeletions),
- •Hypogonadotropic hypogonadism (that might respond to gonadotropin injections),
- •The use of anabolic steroids, illicit drugs, or the consumption of more than 4 alcoholic beverages daily
- •Severe mental health problems requiring medications
- •Current therapy with retinoic acid (e.g. Accutane) or vitamin A.
- •Score of greater than 15 on the Patient health questionnaire (PHQ9).
- •Abnormal serum chemistry values according to local laboratory normal values which indicate liver or kidney dysfunction. Other abnormal lab values may also be exclusionary, at the discretion of the investigator
- •Men with a personal history of serious psychiatric disorders
- •Men currently receiving tetracycline containing medications
- •Men currently receiving phenytoin
- •Men with a history of inflammatory bowel disease
- •Men with a history of bone disease
- •Men who have used isotretinoin within eight weeks of the start of dosing
- •Men with elevated serum triglycerides
研究组 & 干预措施
13-cis retinoic acid
20mg 13-cis retinoic acid twice daily (BID) with meals for 20 weeks
干预措施: 13-cis retinoic acid (Drug)
Calcitriol 0.25 mcg
oral calcitriol 025 mcg BID subjects 11-20 for 20 weeks
干预措施: 13-cis retinoic acid (Drug)
Calcitriol 0.25 mcg
oral calcitriol 025 mcg BID subjects 11-20 for 20 weeks
干预措施: Calcitriol (Drug)
结局指标
主要结局
Millions of Sperm Per Ejaculate
时间窗: Up to 20-weeks
Millions of sperm per ejaculate in men treated with 13-cis retinoic acid
次要结局
未报告次要终点
研究者
John Amory
Professor, General Internal Medicine
University of Washington